On the contrary, the frequencies of CD19+CD24−CD38+ plasmablasts raised in the three non-diabetic groups (CHC-N, CHC-LC and CHC-HCC) compared with the controls (mean, 1.8 ± 0.2, 1.9 ± 0.2, 1.9 ± 0.2 vs. 1 ± 0.2, p = 0.03, p = 0.05, p = 0.007, respectively), with no significant differences among the three non-diabetic groups of patients. The gene discussed is CD19; the disease is hepatocellular carcinoma.